3
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Heterogeneity of Antilymphocyte Antibody in Sle and Its Correlation with Disease Activity

, , , &
Pages 21-28 | Received 24 Jun 1981, Published online: 12 Jul 2009
 

Abstract

The cytotoxic activities of individual lupus sera were demonstrated against Tγ cells, Tγ (-) cells and B cells. Immunoglobulin classes were also determined in these antilymphocyte antibodies (ALA) in SLE. Tγ-speciflc ALA and B-eeU-specific ALA were almost equally distributed as regards IgG-dominant type, mixed IgG and IgM type and IgM dominant type, while IgM dominant type was predominant in Tγ (-(-specific ALA. Only the IgG type of Tγ-specific ALA among these ALA was significantly associated with clinical parameters, including hypocom-plementemia, elevated immune complex levels and high anti-double-stranded (ds) DNA titres. Serial studies on ALA in a typical case of SLE were performed. Active clinical signs were associated with elevated cytotoxicities of IgG type of Tγ-specific ALA and with relatively low cytotoxicities of the IgM type, whereas after massive corticosteroid therapy, these signs disappeared in tact with the reduction in cytotoxic activities of IgG type of the ALA and the relative rise in cytotoxicities of IgM type of the ALA. These results suggested that IgG class of Tγ-specific ALA seemed to play a major role among several types of ALA in SLE.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.